In a recent bid Y-mAbs Therapeutics Inc. [YMAB] faced a contemporary bid of $40.99 yielding a -11.56% decline where 0.23 million shares have exchanged hands over the last week. YMAB amount got a fall by -4.03% or -$1.72 versus $42.71 at the end of the prior session. This change led market cap to move at 1.74B, putting the price 189.48% below the 52-week high and -25.76% above the 52-week low. The company’s stock has a normal trading capacity of 0.23 million shares while the relative volume is 4.22.
On 19, November 2020, Y-mAbs Announces Update on Omburtamab in DIPG. According to news published on Yahoo Finance, Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“DIPG”). Data was presented at the Society for Neuro-Oncology (“SNO”) Virtual Annual Meeting held November 19 through November 21, 2020. The omburtamab data was presented by Dr. Evan Bander from Weill Cornell Medicine.
Analyst Birdseye View:
The most recent analyst activity for Y-mAbs Therapeutics Inc. [NASDAQ:YMAB] stock was on May 05, 2020, when it was Initiated with an Overweight rating from Barclays, which also raised its 12-month price target on the stock to $44. Before that, on November 09, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $65. On May 01, 2020, Janney Initiated a Buy rating. On April 29, 2020, Morgan Stanley Initiated an Equal-weight rating. On December 24, 2019, JP Morgan Initiated an Overweight rating and increased its price target to $39. On November 20, 2019, Guggenheim Initiated a Buy rating. On September 04, 2019, Wedbush Initiated an Outperform rating. On April 01, 2019 H.C. Wainwright Initiated a Buy rating and elevated its amount target to $36.
In the past 52 weeks of trading, this stock has oscillated between a low of $14.16 and a peak of $55.22. At the most recent market close, shares of Y-mAbs Therapeutics Inc. [NASDAQ:YMAB] were valued at $40.99.
The Principal structure of this organization shows its whole liability to whole principal at 1.11 and the whole liability to whole assets at 1.03. It shows enduring liability to the whole principal at 0.85 and enduring liability to assets at 0.01 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 41.53 points at 1st support level, the second support level is making up to 40.36. But as of 1st resistance point, this stock is sitting at 44.97 and at 47.24 for 2nd resistance point.
Y-mAbs Therapeutics Inc. [YMAB] reported its earnings at -$0.82 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.78/share signifying the difference of -0.04 and -5.10% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$1.01 calling estimates for -$0.68/share with the difference of -0.33 depicting the surprise of -48.50%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Y-mAbs Therapeutics Inc. [NASDAQ:YMAB] is 6.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 15.25. Now if looking for a valuation of this stock’s amount to book ratio is 6.24.
The most recent insider trade was by Gad Thomas, President and Chairman, and it was the sale of 4000.0 shares on Nov 16. GILL DAVID N, the Director, completed a sale of 4000.0 shares on Nov 03. On Nov 02, Gad Thomas, President and Chairman, completed a sale of 4000.0 shares.